Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | TOP1 | P11387 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7172534 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL38895 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL31150922 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL458017 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL2315458 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL29754090 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL23067650 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL38896 | 1.00 | LMNA (0.52) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL260109 | 0.93 | LMNA (0.48) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL187021 | 0.93 | LMNA (0.48) | LMNAL3MBTL1TDP1PDE4AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250336063-A1 | Multimodal Deep Learning to Differentiate Tumor Recurrence from Treatment Effect in Human Glioblastoma | UNIV VIRGINIA PATENT FOUNDATION (US) | 2025-10-30 | — | — | US | claimed |
| CN-117500525-A | preparation of pH-adjusted ascorbic acid solutions | 通用电气健康护理有限公司 | 2024-02-02 | — | — | CN | claimed |
| CN-117447543-A | Fluorine-18 marked p-aminophenylboronic acid and preparation method and application thereof | 西安交通大学医学院第一附属医院 | 2024-01-26 | — | — | CN | claimed |
| CN-116194156-A | PET-CT imaging method, contrast medium and pharmaceutical composition for use in said imaging method | 艾迪珀斯股份公司 | 2023-05-30 | — | — | CN | claimed |
| US-11559591-B2 | Ultrasmall nanoparticles labeled with Zirconium-89 and methods thereof | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-01-24 | — | — | US | claimed |
| CN-109154671-B | Radioactivity detection | 赫尔大学 | 2022-10-04 | — | — | CN | claimed |
| WO-2022050478-A1 | COMPLEX INCLUDING ANTIBODY AGAINST DIGOXIGENIN AND USE THEREOF | 국립암센터 | 2022-03-10 | — | — | WO | claimed |
| US-20260137960-A1 | INTERNAL DOSE-ADAPTED AUTOMATED EXTERNAL BEAM RADIATION THERAPY | VARIAN MEDICAL SYSTEMS INC (US) | 2026-05-21 | — | — | US | disclosed |
| WO-2026090353-A1 | METHODS AND RELATED ASPECTS FOR IDENTIFYING TUMOR SUBTYPES | THE JOHNS HOPKINS UNIVERSITY (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260106010-A1 | COMPUTER-AIDED THERAPY FOR TREATING INSULIN RESISTANCE AND/OR RESTORING GLUCOSE HOMEOSTASIS IN A SUBJECT IN NEED | PALTECH (FR) | 2026-04-16 | — | — | US | disclosed |
| EP-4705774-A1 | METHOD FOR THE IN VITRO DIAGNOSIS OF A NEURODEGENERATIVE DISEASE | Université Grenoble Alpes (FR) | 2026-03-11 | — | — | EP | disclosed |
| US-12573050-B2 | Systems and methods for platform agnostic whole body image segmentation | EXINI DIAGNOSTICS AB (SE) | 2026-03-10 | — | — | US | disclosed |
| US-12567155-B2 | Systems and methods for platform agnostic whole body image segmentation | EXINI DIAGNOSTICS AB (SE) | 2026-03-03 | — | — | US | disclosed |
| US-20220079905-A1 | MAGNETIC RESONANCE IMAGING DRUG CONTAINING DEUTERATED SARCOSINE, AND DIAGNOSTIC METHOD USING SAID DRUG | LIMITED LIABILITY COMPANY "SOLVEX" ("SOLVEX" LLC) (RU) | 2022-03-17 | — | — | US | disclosed |
| WO-2022050478-A1 | COMPLEX INCLUDING ANTIBODY AGAINST DIGOXIGENIN AND USE THEREOF | 국립암센터 | 2022-03-10 | — | — | WO | disclosed |
| US-11268958-B2 | Bacteria-specific labeled substrtates as imaging biomarkers to diagnose, locate, and monitor infections | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-03-08 | — | — | US | disclosed |
| US-20220064177-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-03 | — | — | US | disclosed |
| WO-2022029294-A1 | PET-CT IMAGING METHODS, CONTRAST AGENTS AND PHARMACEUTICAL COMPOSITIONS FOR USE IN SAID IMAGING METHODS | ADIPOSS SÁRL (CH) | 2022-02-10 | — | — | WO | disclosed |
| EP-3481437-B1 | PRECURSORS FOR RADIOFLUORINATION | ABX ADVANCED BIOCHEMICAL COMPOUNDS GMBH (DE) | 2022-01-26 | — | — | EP | disclosed |
| EP-3427740-B1 | NOVEL CANCER TREATMENT WITH A COMBINATION OF INOSITOL PHOSPHATE DERIVATIVE AND MAGNESIUM CHLORIDE | PARC GUY (FR) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12573050-B2 | Systems and methods for platform agnostic whole body image segmentation | KLK3, PSMA3, PSMA1 | LMNA 3238/4885L3MBTL1 1082/4885TDP1 2088/4885 |
| US-12567155-B2 | Systems and methods for platform agnostic whole body image segmentation | KLK3, ACP3, PSMA3 | LMNA 2745/4885L3MBTL1 1030/4885TDP1 835/4885 |
| US-20260137960-A1 | INTERNAL DOSE-ADAPTED AUTOMATED EXTERNAL BEAM RADIATION THERAPY | RAD1, RAD50, MRE11 | LMNA 2082/4885L3MBTL1 1537/4885TDP1 1362/4885 |
| US-20260106010-A1 | COMPUTER-AIDED THERAPY FOR TREATING INSULIN RESISTANCE AND/OR RESTORING GLUCOSE HOMEOSTASIS IN A SUBJECT IN NEED | GLP1R, GIPR, SCTR | LMNA 4017/4885L3MBTL1 4184/4885TDP1 4569/4885 |
| US-20220064177-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TP53, SLC2A1, EGFR | LMNA 3924/4885L3MBTL1 3738/4885TDP1 492/4885 |
| US-20220079905-A1 | MAGNETIC RESONANCE IMAGING DRUG CONTAINING DEUTERATED SARCOSINE, AND DIAGNOSTIC METHOD USING SAID DRUG | SLC1A5, SHMT2, TNNI3 | LMNA 1006/4885L3MBTL1 4615/4885TDP1 2387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.